Rudolph Navari to Granisetron
This is a "connection" page, showing publications Rudolph Navari has written about Granisetron.
Connection Strength
0.477
-
Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol. 1995 May; 13(5):1242-8.
Score: 0.133
-
Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin. J Clin Oncol. 1994 Oct; 12(10):2204-10.
Score: 0.128
-
Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother. 2003 Sep; 37(9):1276-86.
Score: 0.059
-
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5.
Score: 0.043
-
Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol. 1998 Apr; 16(4):1568-73.
Score: 0.041
-
Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7.
Score: 0.037
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
Score: 0.035